C6-ceramide enhances Interleukin-12-mediated T helper type 1 cell responses through a cyclooxygenase-2-dependent pathway

Chin Siang Kue, Mi Young Jung, Dae Ho Cho, Tae Sung Kim

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Ceramides, lipid molecules located predominantly within the plasma membrane of a cell, can function as second messengers, and have been known to carry out a number of cellular functions. T helper type 1 (Th1) immune responses are known to be involved in the cellular immunity, which is crucial in the cancer and allergy immunotherapy. This study was designed to evaluate the effects of ceramides on T helper cell responses and their underlying mechanisms. We demonstrated that a cell-permeable C6-ceramide (C6) together with IL-12 enhanced Th1 cell differentiation, whereas C6 alone had no effects, as demonstrated by the increased populations of IFN-γ expressing CD4+ T cells and the up-regulation of IFN-γ production from CD4+ T cells. In contrast, C2-ceramide and long chain ceramides (C16 and C24) did not affect the Th1 responses. C6 treatment was shown to increase the expression of T-bet, a master transcription factor of Th1 responses, in a dose-dependent fashion. Furthermore, C6 increased the expression of cyclooxygenase-2 (COX-2) in CD4+ T cells. The C6-mediated increase of IFN-γ production and IFN-γ expressing CD4+ T cell populations were significantly suppressed by a COX-2 specific inhibitor (NS-398) in a dose-dependent manner. T-bet expression was also decreased by NS-398 treatment, thereby indicating that C6 ceramide enhances Th1 responses via a COX-2 dependent pathway. This result demonstrates that C6 may be utilized in therapies for the treatment of immune diseases such cancer and allergy by enhancing the Th1 activity.

Original languageEnglish
Pages (from-to)601-609
Number of pages9
JournalImmunobiology
Volume217
Issue number6
DOIs
Publication statusPublished - 2012 Jun 1

Fingerprint

Th1 Cells
Cyclooxygenase 2
Interleukin-12
T-Lymphocytes
Ceramides
Hypersensitivity
Cyclooxygenase 2 Inhibitors
Immune System Diseases
Second Messenger Systems
Therapeutics
Helper-Inducer T-Lymphocytes
Cellular Immunity
Immunotherapy
Population
Cell Differentiation
Neoplasms
Transcription Factors
Up-Regulation
Cell Membrane
Lipids

Keywords

  • C6-ceramide
  • Cyclooxygenase-2
  • Interleukin-12
  • T Helper 1 cell
  • T-bet

ASJC Scopus subject areas

  • Immunology
  • Immunology and Allergy
  • Hematology

Cite this

C6-ceramide enhances Interleukin-12-mediated T helper type 1 cell responses through a cyclooxygenase-2-dependent pathway. / Kue, Chin Siang; Jung, Mi Young; Cho, Dae Ho; Kim, Tae Sung.

In: Immunobiology, Vol. 217, No. 6, 01.06.2012, p. 601-609.

Research output: Contribution to journalArticle

@article{e09566cd88d4427486219d4ddc1cb01d,
title = "C6-ceramide enhances Interleukin-12-mediated T helper type 1 cell responses through a cyclooxygenase-2-dependent pathway",
abstract = "Ceramides, lipid molecules located predominantly within the plasma membrane of a cell, can function as second messengers, and have been known to carry out a number of cellular functions. T helper type 1 (Th1) immune responses are known to be involved in the cellular immunity, which is crucial in the cancer and allergy immunotherapy. This study was designed to evaluate the effects of ceramides on T helper cell responses and their underlying mechanisms. We demonstrated that a cell-permeable C6-ceramide (C6) together with IL-12 enhanced Th1 cell differentiation, whereas C6 alone had no effects, as demonstrated by the increased populations of IFN-γ expressing CD4+ T cells and the up-regulation of IFN-γ production from CD4+ T cells. In contrast, C2-ceramide and long chain ceramides (C16 and C24) did not affect the Th1 responses. C6 treatment was shown to increase the expression of T-bet, a master transcription factor of Th1 responses, in a dose-dependent fashion. Furthermore, C6 increased the expression of cyclooxygenase-2 (COX-2) in CD4+ T cells. The C6-mediated increase of IFN-γ production and IFN-γ expressing CD4+ T cell populations were significantly suppressed by a COX-2 specific inhibitor (NS-398) in a dose-dependent manner. T-bet expression was also decreased by NS-398 treatment, thereby indicating that C6 ceramide enhances Th1 responses via a COX-2 dependent pathway. This result demonstrates that C6 may be utilized in therapies for the treatment of immune diseases such cancer and allergy by enhancing the Th1 activity.",
keywords = "C6-ceramide, Cyclooxygenase-2, Interleukin-12, T Helper 1 cell, T-bet",
author = "Kue, {Chin Siang} and Jung, {Mi Young} and Cho, {Dae Ho} and Kim, {Tae Sung}",
year = "2012",
month = "6",
day = "1",
doi = "10.1016/j.imbio.2011.10.021",
language = "English",
volume = "217",
pages = "601--609",
journal = "Immunobiology",
issn = "0171-2985",
publisher = "Urban und Fischer Verlag GmbH und Co. KG",
number = "6",

}

TY - JOUR

T1 - C6-ceramide enhances Interleukin-12-mediated T helper type 1 cell responses through a cyclooxygenase-2-dependent pathway

AU - Kue, Chin Siang

AU - Jung, Mi Young

AU - Cho, Dae Ho

AU - Kim, Tae Sung

PY - 2012/6/1

Y1 - 2012/6/1

N2 - Ceramides, lipid molecules located predominantly within the plasma membrane of a cell, can function as second messengers, and have been known to carry out a number of cellular functions. T helper type 1 (Th1) immune responses are known to be involved in the cellular immunity, which is crucial in the cancer and allergy immunotherapy. This study was designed to evaluate the effects of ceramides on T helper cell responses and their underlying mechanisms. We demonstrated that a cell-permeable C6-ceramide (C6) together with IL-12 enhanced Th1 cell differentiation, whereas C6 alone had no effects, as demonstrated by the increased populations of IFN-γ expressing CD4+ T cells and the up-regulation of IFN-γ production from CD4+ T cells. In contrast, C2-ceramide and long chain ceramides (C16 and C24) did not affect the Th1 responses. C6 treatment was shown to increase the expression of T-bet, a master transcription factor of Th1 responses, in a dose-dependent fashion. Furthermore, C6 increased the expression of cyclooxygenase-2 (COX-2) in CD4+ T cells. The C6-mediated increase of IFN-γ production and IFN-γ expressing CD4+ T cell populations were significantly suppressed by a COX-2 specific inhibitor (NS-398) in a dose-dependent manner. T-bet expression was also decreased by NS-398 treatment, thereby indicating that C6 ceramide enhances Th1 responses via a COX-2 dependent pathway. This result demonstrates that C6 may be utilized in therapies for the treatment of immune diseases such cancer and allergy by enhancing the Th1 activity.

AB - Ceramides, lipid molecules located predominantly within the plasma membrane of a cell, can function as second messengers, and have been known to carry out a number of cellular functions. T helper type 1 (Th1) immune responses are known to be involved in the cellular immunity, which is crucial in the cancer and allergy immunotherapy. This study was designed to evaluate the effects of ceramides on T helper cell responses and their underlying mechanisms. We demonstrated that a cell-permeable C6-ceramide (C6) together with IL-12 enhanced Th1 cell differentiation, whereas C6 alone had no effects, as demonstrated by the increased populations of IFN-γ expressing CD4+ T cells and the up-regulation of IFN-γ production from CD4+ T cells. In contrast, C2-ceramide and long chain ceramides (C16 and C24) did not affect the Th1 responses. C6 treatment was shown to increase the expression of T-bet, a master transcription factor of Th1 responses, in a dose-dependent fashion. Furthermore, C6 increased the expression of cyclooxygenase-2 (COX-2) in CD4+ T cells. The C6-mediated increase of IFN-γ production and IFN-γ expressing CD4+ T cell populations were significantly suppressed by a COX-2 specific inhibitor (NS-398) in a dose-dependent manner. T-bet expression was also decreased by NS-398 treatment, thereby indicating that C6 ceramide enhances Th1 responses via a COX-2 dependent pathway. This result demonstrates that C6 may be utilized in therapies for the treatment of immune diseases such cancer and allergy by enhancing the Th1 activity.

KW - C6-ceramide

KW - Cyclooxygenase-2

KW - Interleukin-12

KW - T Helper 1 cell

KW - T-bet

UR - http://www.scopus.com/inward/record.url?scp=84860235121&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84860235121&partnerID=8YFLogxK

U2 - 10.1016/j.imbio.2011.10.021

DO - 10.1016/j.imbio.2011.10.021

M3 - Article

C2 - 22112438

AN - SCOPUS:84860235121

VL - 217

SP - 601

EP - 609

JO - Immunobiology

JF - Immunobiology

SN - 0171-2985

IS - 6

ER -